Showing results (311-320 of 831) with videos related to

Sort By:
Pageof 84
Clinical Lymphoma, Myeloma & Leukemia|June 25, 2013
Retrospective analysis of prognostic factors associated with response and overall survival by baseline marrow blast percentage in patients with myelodysplastic syndromes treated with decitabineElias Jabbour, Hagop Kantarjian, Susan O'Brien, et al.
Clinical Lymphoma, Myeloma & Leukemia|May 18, 2011
Significance of thrombocytopenia in myelodysplastic syndromes: associations and prognostic implicationsAli Al Ameri, Elias Jabbour, Guillermo Garcia-Manero, et al.
Cancer|April 30, 2009
Dasatinib early intervention after cytogenetic or hematologic resistance to imatinib in patients with chronic myeloid leukemiaAlfonso Quintás-Cardama, Jorge E Cortes, Susan O'Brien, et al.
Blood|October 30, 2010
Predictive factors for outcome and response in patients treated with second-generation tyrosine kinase inhibitors for chronic myeloid leukemia in chronic phase after imatinib failureElias Jabbour, Hagop Kantarjian, Susan O'Brien, et al.
Plos One|August 24, 2010
JAK2 exon 14 deletion in patients with chronic myeloproliferative neoplasmsWanlong Ma, Hagop Kantarjian, Xi Zhang, et al.
Cancer|May 15, 2009
Survival is poorer in patients with secondary core-binding factor acute myelogenous leukemia compared with de novo core-binding factor leukemiaGautam Borthakur, E Lin, Nitin Jain, et al.
Cancer|June 24, 2005
Outcome of patients with acute myelogenous leukemia after second salvage therapyFrancis Giles, Susan O'Brien, Jorge Cortes, et al.
Cancer|April 30, 2005
Interferon alpha therapy for patients with essential thrombocythemia: final results of a phase II study initiated in 1986Rashid Saba, Elias Jabbour, Francis Giles, et al.
Cancer|September 13, 2007
Phase 1 study of tipifarnib in combination with imatinib for patients with chronic myelogenous leukemia in chronic phase after imatinib failureJorge Cortes, Alfonso Quintás-Cardama, Guillermo Garcia-Manero, et al.
Blood|August 4, 2007
Establishment of baseline toxicity expectations with standard frontline chemotherapy in acute myelogenous leukemiaEhab Atallah, Jorge Cortes, Susan O'Brien, et al.
Pageof 84